Liquidation: Unity Biotechnology, Inc.

Form Type: 8-K

Filing Date: 2025-06-30

Corporate Action: Liquidation

Type: New

Accession Number: 000095017025091210

Filing Summary: On June 27, 2025, Unity Biotechnology, Inc. was notified by Nasdaq that it no longer meets the requirements for continued listing, citing lack of an operating business and insufficient stockholders' equity. The company’s board approved a Plan of Dissolution, stating it to be in the best interests of Unity and its stockholders, and intends to seek stockholder approval at a special meeting. Major director resignations occurred the same day, reducing the board from eight to one member. Key officers, including the CEO and CFO, also departed, and Craig R. Jalbert was appointed as the new President and Corporate Secretary. The company aims to maximize value for creditors and stockholders through asset monetization, despite not finding a viable alternative to dissolution. A proxy statement regarding the planned dissolution will be filed with the SEC.